ES8304946A1 - "un procedimiento para la preparacion de 5-halopirimidin-2-onas". - Google Patents

"un procedimiento para la preparacion de 5-halopirimidin-2-onas".

Info

Publication number
ES8304946A1
ES8304946A1 ES509219A ES509219A ES8304946A1 ES 8304946 A1 ES8304946 A1 ES 8304946A1 ES 509219 A ES509219 A ES 509219A ES 509219 A ES509219 A ES 509219A ES 8304946 A1 ES8304946 A1 ES 8304946A1
Authority
ES
Spain
Prior art keywords
ring
groups
heterocyclic
saturated
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES509219A
Other languages
English (en)
Other versions
ES509219A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nyegaard and Co AS
Original Assignee
Nyegaard and Co AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyegaard and Co AS filed Critical Nyegaard and Co AS
Publication of ES509219A0 publication Critical patent/ES509219A0/es
Publication of ES8304946A1 publication Critical patent/ES8304946A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE 5-HALOPIRIMIDIN-2-ONAS, DE FORMULA GENERAL (I), EN DONDE X REPRESENTA UN ATOMO DE HALOGENO; R Y R REPRESENTAN CADA UNO DE ELLOS UN ATOMO DE HIDROGENO O UN GRUPO ALCOHILO DE C <- ; ~AHET~B REPRESENTA UN ANILLO HETEROCICLICO SATURADO, INSATURADO O AROMATICO; Y ~AALC~B REPRESENTA UN GRUPO HIDROCARBILO ALIFATICO, DIVALENTE, DE CADENA NORMAL O RAMIFICADA, Y DE SUS SALES FARMACEUTICAMENTE ACEPTABLES. CONSISTE EN CERRAR EL ANILLO DE UN COMPUESTO DE FORMULA (I), EN DONDE R , R , X Y ~AALC~B TIENEN LOS SIGNIFICADOS YA INDICADOS, Y Z REPRESENTA UN GRUPO CAPAZ DE CICLISACION PARA FORMAR EL GRUPO ~AHET~B, PARA OBTENER UN COMPUESTO DE FORMULA (I). DE APLICACION EN LA PREPARACION DE FARMACOS PARA COMBATIR LA PROLIFERACION CELULAR ANORMAL.
ES509219A 1980-01-07 1982-02-01 "un procedimiento para la preparacion de 5-halopirimidin-2-onas". Expired ES8304946A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8000381 1980-01-07

Publications (2)

Publication Number Publication Date
ES509219A0 ES509219A0 (es) 1983-03-16
ES8304946A1 true ES8304946A1 (es) 1983-03-16

Family

ID=10510470

Family Applications (2)

Application Number Title Priority Date Filing Date
ES498337A Expired ES8205399A1 (es) 1980-01-07 1981-01-05 Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas
ES509219A Expired ES8304946A1 (es) 1980-01-07 1982-02-01 "un procedimiento para la preparacion de 5-halopirimidin-2-onas".

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES498337A Expired ES8205399A1 (es) 1980-01-07 1981-01-05 Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas

Country Status (13)

Country Link
US (1) US4399140A (es)
EP (1) EP0032131B1 (es)
JP (1) JPS56150087A (es)
AT (1) ATE4715T1 (es)
AU (1) AU543939B2 (es)
CA (1) CA1168239A (es)
DE (1) DE3160886D1 (es)
DK (1) DK149892B (es)
ES (2) ES8205399A1 (es)
IE (1) IE50765B1 (es)
NO (1) NO810024L (es)
NZ (1) NZ195947A (es)
ZA (1) ZA8164B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197715A (en) * 1980-07-15 1984-12-14 Glaxo Group Ltd Substituted pyrimin-2-ones and pharmaceutical compositions
NZ197714A (en) * 1980-07-15 1984-11-09 Glaxo Group Ltd Substituted pyrimidin-2-ones and pharmaceutical compositions
CA1180710A (en) * 1981-01-09 1985-01-08 Tore Benneche Substituted pyrimidin-2-ones and the salts thereof
EP0087326B1 (en) * 1982-02-24 1987-05-13 Nycomed As Substituted pyrimidin-2-ones and the salts thereof
SU1235864A1 (ru) * 1983-03-11 1986-06-07 Отделение ордена Ленина института химической физики АН СССР Нитроксильные производные 5-фторурацила,обладающие противоопухолевой активностью
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
US9809588B2 (en) 2014-07-03 2017-11-07 Board Of Regents, The University Of Texas System GLS1 inhibitors for treating disease
WO2016004417A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
CN107921044B (zh) 2015-06-30 2022-01-21 德州大学系统董事会 用于治疗疾病的gls1抑制剂
MX384732B (es) 2015-12-22 2025-03-14 Univ Texas Formas de sales y polimorfos de (r)-1-(4-(6-(2-(4-(3,3-difluorociclobutoxi)-6-metilpiridin-2-il)acetamido)piridazin-3-il)-2-fluorobutil)-n-metil-1h-1,2,3-triazol-4-carboxamida.
EP3697764B1 (en) 2017-10-18 2025-06-11 Board Of Regents, The University Of Texas System Gls-1 inhibitors for use in the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833586A (en) * 1971-03-25 1974-09-03 Morton Norwich Products Inc 1-(substituted benzyl)-2-(1h)pyrimidones and 1-(substituted benzyl)tetrahydro-2-(1h)pyrimidones
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4003900A (en) * 1976-03-11 1977-01-18 Morton-Norwich Products, Inc. 1-Benzyl-5-chloro-2-(1H)-pyrimidone
US4052399A (en) * 1976-09-13 1977-10-04 Morton-Norwich Products, Inc. 1-[2-(Hexahydro-1H-azepino)ethyl]-2(1H)pyrimidone dihydrochloride
US4052400A (en) * 1976-10-29 1977-10-04 Morton-Norwich Products, Inc. Hypertensive 1-substituted 2(1h)-pyrimidones

Also Published As

Publication number Publication date
DK149892B (da) 1986-10-20
ES509219A0 (es) 1983-03-16
ES498337A0 (es) 1982-06-01
EP0032131B1 (en) 1983-09-21
AU543939B2 (en) 1985-05-09
CA1168239A (en) 1984-05-29
IE810013L (en) 1981-07-07
AU6601681A (en) 1981-07-16
NZ195947A (en) 1983-09-02
JPS56150087A (en) 1981-11-20
DE3160886D1 (en) 1983-10-27
DK3281A (da) 1981-07-08
ATE4715T1 (de) 1983-10-15
US4399140A (en) 1983-08-16
NO810024L (no) 1981-07-08
ES8205399A1 (es) 1982-06-01
ZA8164B (en) 1982-03-31
EP0032131A1 (en) 1981-07-15
IE50765B1 (en) 1986-07-09

Similar Documents

Publication Publication Date Title
MY101359A (en) 7-acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them, their starting compounds and their preparation
ES8304947A1 (es) &#34;procedimiento para la preparacion de pirimidin-2-sulfuros y sus s-oxidos&#34;.
NZ227436A (en) Cell proliferation inhibiting composition comprising a substituted styrene derivative
DE3160886D1 (en) 5-halo-pyrimidin-2-ones, the salts thereof, processes for their preparation and pharmaceutical compositions containing them
ES481729A1 (es) Procedimiento para la preparacion de derivados de 1,2-dihi- droquinolein-2-onas.
GB1184714A (en) Di- and Tri-Phenylpropyl Piperazine Derivatives
ES2000456A6 (es) Procedimiento para preparar deirvados de acido eicosatriinoico-5,8,11 y utilizacion de estos en composiciones farmaceuticas y cosmeticas.
ES8307758A1 (es) &#34;un procedimiento para la preparacion de pirimidin-2-onas sustituidas&#34;.
ES8401755A1 (es) Procedimiento para la preparacion de derivados de tiometilpiridina.
DK661088A (da) N-(23-vinblastinoyl)derivater af 1-aminomethylphosphonsyre, fremgangsmaade til deres fremstilling og farmaceutiske midelr indeholdende dem
GB973882A (en) Benzyl-guanidines,their preparation and pharmaceutical compositions containing them
ES8308860A1 (es) &#34;un procedimiento para la preparacion de pirimid-2-onas&#34;.
ES8300750A1 (es) Un procedimiento para la preparacion de pirimidin-2-onas sustituidas
HUP0203696A2 (hu) Sejtburjánzásgátló hatású helyettesített bisz-indolil-maleimidek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES8401461A1 (es) Procedimiento para la preparacion de derivados de 2-pirrolin-3-carbonitrilo.
GB1049285A (en) Guanidine and dihydroimidazole derivatives
ES428535A1 (es) Un procedimiento para la preparacion de cicloserina n-sus- tituida.
ES443559A1 (es) Un procedimiento para la obtencion de derivados de alanina -n,n-disustituidos.
ES450211A1 (es) Procedimiento para la obtencion de nuevos derivados de la 1-hidroxi-benzo-2,3,1-diazaborina.
ES356259A1 (es) Un procedimiento para la preparacion de compuestos hetero- ciclicos de actividad terapeutica.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19971201